Drug General Information (ID: DDI3HLO5X0)
  Drug Name Imipramine Drug Info Apraclonidine Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antidepressants Ophthalmic Glaucoma Agents
  Structure

 Mechanism of Imipramine-Apraclonidine Interaction (Severity Level: Moderate)
     Additive CNS depression effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Imipramine Apraclonidine
      Mechanism CNS depression effects CNS depression effects
      Key Mechanism Factor 1
Factor Name CNS depression effects
Factor Description CNS depressants are drugs that inhibit or suppress brain activity and can reduce mental and physical processes. Excessive CNS depression can lead to decreased heart rate, slow breathing (less than 10 breaths per minute), extreme confusion or loss of memory, nausea and vomiting, poor judgment, blue lips or fingertips, irritability and aggression, and clammy or cold skin.
      Mechanism Description
  • Additive CNS depression effects by the combination of Imipramine and Apraclonidine 

Recommended Action
      Management Patients receiving topical alpha-2 adrenergic receptor agonists in combination with tricyclic antidepressants should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, confusion, hypotension and syncope, and counseled to avoid activities requiring mental alertness until they know how these agents affect them. Patients should also avoid rising abruptly from a sitting or recumbent position and notify their doctor if they experience orthostasis or tachycardia. No data are available on the level of circulating catecholamines after withdrawal of a topical alpha-2 adrenergic receptor agonist. Since tricyclic antidepressants can affect the metabolism and uptake of circulating amines, caution is advised.

References
1 Product Information. Iopidine (apraclonidine). Alcon Laboratories Inc, Fort Worth, TX.
2 King MH, Richards DW "Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy." Am J Ophthalmol 110 (1990): 308-9. [PMID: 2204271]
3 Pekdemir M, Yanturali S, Karakus G "More than just an ocular solution." Emerg Med J 22 (2005): 753-4. [PMID: 16189050]